Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses

Li, Shanfeng; Peng, Liang; Zhao, Wei; Zhong, Hua; Zhang, Fuchun; Zeng, Yan; Cao, Hong

doi:10.1016/j.vaccine.2011.03.002

Cited by 36 publications

(32 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epitope-based vaccines have been widely reported to show promising results for a range of viral, bacterial and parasitic diseases [26,27,28]. Recent epitope studies of hMPV have mainly focused on CTL epitopes, which were important to viral clearance.…”

Section: Discussionmentioning

confidence: 99%

Design and Evaluation of a Multi-Epitope Peptide of Human Metapneumovirus

Guo

Kong

et al. 2015

Intervirology

View full text Add to dashboard Cite

Objectives: No licensed vaccines or therapeutic agents for human metapneumovirus (hMPV) infection exist to date. We aimed to construct a multi-epitope peptide (MEP) of hMPV to show promising results for epitope-based vaccine development. Methods: Six independent algorithms were screened to predict B-cell epitopes of hMPV, and three algorithms were used to predict cytotoxic T lymphocyte and T helper (Th) lymphocyte epitopes. Predicted epitopes were assembled in series with the spacers GPGPG and KK introduced, termed MEP. Recombinant mep genes were inserted into pET32a(+) plasmid and expressed in Escherichia coli strain BL21 (DE3). BALB/c mice were immunized with MEP with different adjuvants. Antibody titer, lymphocyte proliferation, cytotoxic T lymphocyte (CTL) activity and splenocyte cytokines were detected 2 weeks later after the last immunization. Microneutralization assay was used to detect neutralizing antibodies. Results: Six B-cell epitopes, four CTL epitopes and two Th epitopes were screened to construct the mep gene. Expressed MEP induced >10⁴ antibodies in BALB/c mice, and produced anti-MEP antibody reacting with hMPV strains specifically as detected in indirect fluorescent assay (the titer was 160). The lymphocyte proliferation index, CTL activity and splenocyte cytokines of the MEP immunization groups were higher than in the control group (p < 0.05). Both IgG1 and IgG2a antibodies could be detected in the different groups, and balanced Th1/Th2 cytokines were secreted by splenocytes in these groups. The mean neutralizing titers of the MEP+CpG ODN, MEP+Alum and MEP+Alum+ CpG ODN groups were 87 (95% CI 50-126), 93 (95% CI 67-121) and 96 (95% CI 69-147), respectively. Conclusion: MEP of hMPV elicited both strong humoral immunity and cell-mediated immunity in mice. The anti-MEP serum could neutralize hMPV infection in vitro. Joint use of CpG ODN and aluminum hydroxide adjuvants obtained the best immune effects. This study may contribute to hMPV epitope-based vaccine development.

show abstract

Section: Discussionmentioning

confidence: 99%

Design and Evaluation of a Multi-Epitope Peptide of Human Metapneumovirus

Guo

Kong

et al. 2015

Intervirology

View full text Add to dashboard Cite

show abstract

“…that DENV E protein has many B-cell-specific epitopes that can stimulate B cells to produce neutralization antibodies against virus infection (32,33). In this work, the DENV E protein was successfully expressed in the recombinant DENV VLPs and stimulated the production of neutralizing antibodies that are particularly important to block dengue virus entry into target cells.…”

Section: Discussionmentioning

confidence: 99%

Retracted: Immunological properties reveal the monovalent and bivalent recombinant dengue virus‐like particles as candidate vaccine for dengue

2015

Microbiology and Immunology

View full text Add to dashboard Cite

We aimed to systematically analyze the immunological properties of monovalent and bivalent dengue virus-like particles (DENV VLPs) prepared in our study and provided basis for the development of DENV VLPs as a promising non-infectious candidate vaccine for dengue infection. The DENV-1/2 VLPs were prepared in the GAP promoter-based P.pastoris expression system using α-factor secretion signal. Groups of mice were immunized by monovalent and bivalent VLPs compared with inactivated virions and PBS. Then, the humoral immune response in mice were tested by ELISA, immunofluorescence and neutralization assay. ELISA and Enzyme linked immunospot assay were performed for investigating cytokines production after virus challenge in vivo and in vitro, respectively. Besides, the protection ability of VLPs was assessed by passive protection assay in suckling mice. The recombinant DENV-1/2 VLPs were successfully expressed with α-factor secretion signal. Sera of mice immunized with monovalent and bivalent VLPs elevated the specific antibodies level comparable to inactivated virions group. The monovalent and bivalent VLPs induced specific cellular immune response as confirmed by ELISPOT. The PRNT 50 titers of monovalent and bivalent VLPs sera against DENV-1/2 were different ranging from 16 to 64. Moreover, anti-monovalent and anti-bivalent DENV VLPs sera displayed protective capacity in survival rate and morbidity. Monovalent and bivalent VLPs showed attracting vaccine effect for dengue virus. The multivalent VLPs may be promising for preventing different types of dengue virus.

show abstract

“…This peptide binds with high or intermediate affinity to the most common HLA-DR types, and allows it to activate a wide range of CD4 + T cells (70). The addition of PADRE epitopes is used, for example, in Dengue virus and HBV virus vaccine development, showing promising results in vivo (71, 72). Another group of universal T helper epitopes are natural tetanus sequences, which are very promiscuous in their capacity to bind to MHC class II, and thereby very efficient in acting as a co-stimulus (73).…”

Section: Co-stimulation and Peptide Vaccinationmentioning

confidence: 99%

T Cell Responses to Viral Infections â€“ Opportunities for Peptide Vaccination

et al. 2014

View full text Add to dashboard Cite

An effective immune response against viral infections depends on the activation of cytotoxic T cells that can clear infection by killing virus-infected cells. Proper activation of these T cells depends on professional antigen-presenting cells, such as dendritic cells (DCs). In this review, we will discuss the potential of peptide-based vaccines for prevention and treatment of viral diseases. We will describe features of an effective response against both acute and chronic infections, such as an appropriate magnitude, breadth, and quality and discuss requirements for inducing such an effective antiviral immune response. We will address modifications that affect presentation of vaccine components by DCs, including choice of antigen, adjuvants, and formulation. Furthermore, we will describe differences in design between preventive and therapeutic peptide-based vaccines. The ultimate goal in the design of preventive vaccines is to develop a universal vaccine that cross-protects against multiple strains of the virus. For therapeutic vaccines, cross-protection is of less importance, but enhancing existing T cell responses is essential. Although peptide vaccination is successful in inducing responses in human papillomavirus (HPV) infected patients, there are still several challenges such as choosing the right target epitopes, choosing safe adjuvants that improve immunogenicity of these epitopes, and steering the immune response in the desired direction. We will conclude with an overview of the current status of peptide vaccination, hurdles to overcome, and prospects for the future.

show abstract

Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses

Cited by 36 publications

References 42 publications

Design and Evaluation of a Multi-Epitope Peptide of Human Metapneumovirus

Design and Evaluation of a Multi-Epitope Peptide of Human Metapneumovirus

Retracted: Immunological properties reveal the monovalent and bivalent recombinant dengue virus‐like particles as candidate vaccine for dengue

T Cell Responses to Viral Infections â€“ Opportunities for Peptide Vaccination

Contact Info

Product

Resources

About